PPARs The currently approved PPAR agonists include fenofibrate, pioglitazone hydrochloride, and rosiglitazone, which are primarily used to treat metabolic syndrome, CVD, and diabetes and have shown significant efficacy in clinical studies
NAD+ peptide therapy pricing shows what the typical cost structure looks like: nasal spray formulations cost $144-199 per month, while injectable forms range from $155-235 monthly
doi: 10.1016/S0022-3999(01)00315-4 Summary Keywords Sensewear armband, myalgic encephalomyelitis/chronic fatigue syndrome, vitamin B12 nasal drops, vitamin B12 serum concentration, RAND 36 questionnaire Citation van Campen CLMC, Riepma K and Visser FC (2019) Open Trial of Vitamin B12 Nasal Drops in Adults With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Comparison of Responders and Non-Responders
Lajin, B., and A
A separate regulatory status This is the major asymmetry between the two